We compared the efficacy and safety of ipratropium bromide/albuterol delivered via Respimat â inhaler, a novel propellant-free inhaler, versus chlorofluorocarbon (CFC)-metered dose inhaler (MDI) and ipratropium Respimat â inhaler in patients with COPD. This was a multinational, randomized, double-blind, double-dummy, 12-week, parallelgroup, active-controlled study. Patients with moderate to severe COPD were randomized to ipratropium bromide/albuterol (20/100 mcg) 
Summary
We compared the efficacy and safety of ipratropium bromide/albuterol delivered via Respimat â inhaler, a novel propellant-free inhaler, versus chlorofluorocarbon (CFC)-metered dose inhaler (MDI) and ipratropium Respimat â inhaler in patients with COPD. This was a multinational, randomized, double-blind, double-dummy, 12-week, parallelgroup, active-controlled study. Patients with moderate to severe COPD were randomized to ipratropium bromide/albuterol (20/100 mcg) Respimat â inhaler, ipratropium bromide/albuterol MDI [36 mcg/206 mcg (Combivent â Inhalation Aerosol MDI)], or ipratropium bromide (20 mcg) Respimat â inhaler. Each medication was administered four times daily. Serial spirometry was performed over 6 h (0.15 min, then hourly) on 4 test days. The primary efficacy variable was forced expiratory volume in 1 s (FEV 1 ) change from test day baseline at 12 weeks.
Introduction
The effective treatment of patients with airway disease such as chronic obstructive pulmonary disease (COPD) requires efficient delivery of medical aerosols to the lungs. Inhaled bronchodilators, the cornerstone treatment for COPD, are commonly delivered to the lungs via metered dose inhalers (MDI) which utilize chlorofluorocarbons (CFC) or hydrofluoroalkane (HFA) propellants to generate an aerosolized medication. Respimat â inhalation spray is a propellant-free, multi-dose inhaler designed as an alternative to MDIs. It uses mechanical energy from a pretensioned spring to generate a medical aerosol, rather than CFC propellants which contribute to ozone-depletion, with subsequent negative environmental and public health impacts.
The Respimat â inhaler generates a slow moving aerosol over 1.5 s facilitating coordination with inhalation and a fine particle spray (<5.8 mm), improving efficiency of drug delivery to the lungs. 1, 2 Studies have shown that lung deposition was approximately doubled and oropharyngeal deposition was significantly reduced with Respimat â inhaler compared to MDI. 3e5 Use of the Respimat â inhaler is independent of inspiratory effort and the device provides the patient with a dose indicator, a locking mechanism that prevents delivery of partial doses; and for ipratropium bromide/albuterol Respimat â inhaler (20/100 mcg), the convenience of single puff dosing.
Clinical studies have established that a combination therapy of ipratropium bromide, an anticholinergic bronchodilator, and albuterol, a b 2 -adrenergic bronchodilator, results in an additive bronchodilator effect. 6, 7 Use of the combination therapy also results in improved patient outcomes (fewer Emergency Room visits, hospitalizations and a subsequent reduction in hospital length of stay) and compliance, compared with concomitant use of separate ipratropium and albuterol MDIs. 8 The aim of this study was to determine the efficacy and safety of the Respimat â inhaler during combination treatment with ipratropium bromide/albuterol 20 ) and a smoking history of 10 pack-yrs were included. Patients with a confounding disease that would put the patient at risk because of study participation or potentially influence the results of the study were excluded. Other exclusion criteria included: known hypersensitivity to anticholinergic or betaagonist therapy; concomitant use of drugs contraindicated with anticholinergic or beta-agonist therapy; elevated blood eosinophil count (600/nm 3 ); respiratory infection within 6 weeks prior to screening; regular daytime oxygen therapy; use of antihistamines, oral corticosteroids at unstable doses (i.e. <6 weeks on a stable dose or exceeding the equivalent of prednisone 10 mg daily), initiation of inhaled steroid or change in dose < 6 weeks prior to screening; use of beta-blockers, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants < 30 days before baseline period or during treatment period. Long-acting and short-acting inhaled anticholinergic agents and long-acting beta agonists were not allowed during the conduct of the study. All patients were provided with albuterol MDI to use as needed.
Study design
A multinational (13 countries), multi-center (179 centers), randomized, double-blind, double-dummy, parallel design, active controlled non-inferiority study was performed to compare efficacy and safety of orally inhaled ipratropium bromide/albuterol 20 Helsinki (1996) and GCP. All patients provided written informed consent prior to participation in the study and the study was approved by the institutional ethics review boards used by participating investigators. The study was sponsored by Boehringer Ingelheim.
Efficacy endpoints
The three co-primary endpoints in this study included FEV 1 change from test-day baseline at Day 85 for: (1) Secondary endpoints included FEV 1 at Day 1, 29, 57, peak FEV 1 (maximum FEV 1 value within the first 2 h after study drug administration), peak FEV 1 response (the maximum change in FEV 1 from test-day baseline within the first 2 h after study drug administration), time to peak FEV 1 response, median time to onset of a therapeutic response, median duration of therapeutic response, FVC AUC 0e6 , AUC 0e4, AUC 4e6 , and peak FVC response (maximum change in FVC from test-day baseline within the first 2 h after study drug administration) on Day 1, 29, 57, 85. For the purpose of this study, a therapeutic response during the 6-h PFT day was considered to have been achieved if a FEV 1 measurement of at least 1.15 times the pre-dose value was recorded at any time during the first 2 h of observation. Termination of therapeutic response was defined as the first fall below 1.15 times pre-dose FEV 1 on two consecutive measurements after therapeutic response.
Safety endpoints
Adverse and serious adverse events were monitored throughout the 2 week baseline and 12 week treatment period. Pulse rate and blood pressure were measured at baseline and on each test day (Day 1, 29, 57, 85) before PFT. Baseline and end-of-study (week 12) physical examination and electrocardiogram were also recorded.
Statistical analysis
The three co-primary endpoints were analyzed using analysis of covariance (ANCOVA) with fixed effects for treatment and pooled investigator site and day 1 baseline as a covariate. Using a standard deviation of 180 mL for each of the three co-primary endpoints, the sample size of 400 patients per treatment group provided a 97% chance of rejecting each of the three null hypotheses. Treated Figure 1 Overall scheme of the study design. During the 2 week baseline run-in phase, all patients took ipratropium MDI at a dosage of 17 mcg, two actuations q.i.d. and albuterol MDI as needed. During the 12 week treatment period, patients took study medication q.i.d.: on arising, mid-day, early evening, and before retiring. PFT, pulmonary function test; q.i.d., four times daily; *1 actuation; y2 actuations; z as needed.
patients from the full analysis set who had valid baseline PFT data and 4 time points PFT data during the first 3 h after the study drug administration on at least 1 test day were included in the AUC 0e6 and AUC 0e4 efficacy analysis. As a subset of the analysis set for the AUC 0e6 and AUC 0e4 efficacy analysis, treated patients who had all 3 PFT data at 4, 5, 6 h after drug administration on at least 1 of the last 3 test days were included in the AUC 4e6 efficacy analysis.
ANCOVA model was also used to analyze secondary endpoints. Onset and duration of therapeutic response and time to peak FEV 1 response were summarized by simple medians. Safety analyses were summarized descriptively. Adverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 10.1. In order to see combined occurrence rates of medically related adverse events, multiple MedDRA preferred terms were combined into a more meaningful single clinical pre-defined collapsed term. Randomized patients from the treated set who received 1 dose of study medication were included in the safety analysis.
Results

Patient disposition and characteristics
A total of 2462 patients signed informed consent and were enrolled in the study. One thousand four hundred and eighty patients were randomized and received treatment, and 1460 were evaluable (98.6%) (Fig. 2) . Baseline characteristics were comparable among randomized treatment groups (Table 1 ). The mean age of the treated patient population was 64.1 years; 65.4% of the treated patients were male and 89.0% were white. The mean duration of COPD was 8.4 years. All patients were current smokers (n Z 600, 41.1%) or ex-smokers (n Z 860, 58.9%) with a mean percent predicted FEV1 of 41.4% and mean FEV 1 /FVC of 44.8% at screening. The percentages of patients taking any pulmonary medication were balanced across the three treatment groups. Most frequently used classes of concomitant pulmonary medications at the time of screening were inhaled short-acting beta agonists (62%), inhaled corticosteroids (44%), inhaled short-acting anticholinergic agents (38%), inhaled long-acting beta agonists (31%). Less frequently used were: methylxanthines (10%), inhaled long-acting anticholinergic agents (9%), and oxygen (4%). Long-acting inhaled anticholinergic agents and longacting beta agonists were not allowed during the conduct of the study. The withdrawal rates were similar for the three treatment groups (12.6% ipratropium Respimat â inhaler; 11.2% ipratropium bromide/albuterol MDI; 9.9% ipratropium bromide/albuterol Respimat â inhaler).
Spirometry
Comparable bronchodilation was achieved with ipratropium bromide/albuterol Respimat â inhaler and ipratropium bromide/albuterol MDI as shown by FEV 1 change from testday baseline from 0e6, 0e4 and 4e6 h at 12 weeks, respectively (Fig. 3A) . On test Day 85, the ipratropium bromide/albuterol Respimat â inhaler group was non-inferior to the ipratropium bromide/albuterol MDI group at 0e6 h, and was superior to the ipratropium Respimat â inhaler group with a difference of 0.047 l (P < 0.0001) at 0e4 h in favor of ipratropium bromide/albuterol Respimat â inhaler. At 4e6 h, the bronchodilation achieved with ipratropium bromide/albuterol Respimat â inhaler group was non-inferior to that achieved with the mono-component ipratropium Respimat â inhaler group (Fig. 3B) .
Ipratropium bromide/albuterol Respimat â inhaler significantly improved FEV 1 compared with the monocomponent ipratropium Respimat â inhaler at 0e4 and 0e 6 h on all test days. (Fig. 4) The results from the secondary FEV 1 and FVC endpoints were consistent with the primary FEV 1 data. Peak FEV 1 , peak FEV 1 response (Fig. 5) 
Safety
Exposure across treatment groups was similar with a mean of 80.1 days. The total incidence of adverse events was comparable across treatment groups (Table 2) . Respiratory events were the most frequently reported adverse events and were predominately comprised of COPD exacerbations. There were no differences among the treatment groups in the frequency of potential anticholinergic class adverse events (2.1% ipratropium Respimat â inhaler, 2.0% ipratropium bromide/albuterol MDI, 1.6% ipratropium bromide/ albuterol Respimat â inhaler). The majority of these events were dry mouth (0.7%) and tremor (0.3%). The highest frequency of possible beta-agonist-related adverse events occurred in the ipratropium Respimat â inhaler group (9.1%), whereas both ipratropium bromide/albuterol groups were comparable (7.2% and 7.5% ipratropium bromide/ albuterol Respimat â inhaler and MDI, respectively, non- None of the deaths were considered related to study treatment. There were no clinically significant differences in vital signs for all treatment groups.
Discussion
The aim of our study was to determine the efficacy and safety of ipratropium bromide/albuterol delivered via the Respimat â inhaler compared with this bronchodilator combination delivered by MDI and with ipratropium alone via the Respimat â inhaler. Test drugs were administered four times daily in patients with moderate to severe COPD over a 12-week study period. Since we included ipratropium in all three treatment arms, our study was not designed to evaluate the efficacy or safety of this drug. Rather, we were interested in evaluating its combination with albuterol delivered via this novel delivery device.
Previous dose-ranging studies and a Phase III trial indicated that a higher dose of ipratropium bromide/albuterol administered via the Respimat â inhaler (40 mcg/200 mcg) was also more effective than the monotherapy of ipratropium bromide (40 mcg) Respimat â inhaler but provided minimal additional bronchodilator effect over the ipratropium bromide/albuterol Respimat â inhaler 20/100 mcg dose chosen for our study. 11 Additionally the 40/200 mcg dose was equivalent in bronchodilator activity to that of the MDI (36 mcg/206 mcg) formulation, a goal of the formulation, since the Respimat inhaler is intended as an alternative to the MDI. 11 Pharmacokinetic data from our study has shown comparable ipratropium bromide systemic exposure for all three investigational treatments of this trial, and less systemic exposure for albuterol with ipratropium bromide/ albuterol Respimat â inhaler (20 mcg/100 mcg) than that with ipratropium bromide/albuterol MDI (36/206 mcg). 12 The 20 mcg dose of ipratropium with 100 mcg of albuterol maintained the 1:5 ratio of ipratropium bromide to Missing data were imputed by carrying either the lowest or last value forward depending on why the data were missing. Means (SE) were adjusted for treatment baseline and pooled centre (fixed). A separate ANCOVA was fitted for each time point and test day. FEV 1 , forced expiratory volume in 1s. Test day 85 baseline FEV 1 (in liters) was 1.112. 1.106 and 1.114 for ipratropium bromide/albuterol Respimat â inhaler, ipratropium bromide/albuterol MDI, and ipratropium bromide Respimat â inhaler, respectively. B. Day 85 mean treatment differences and 95% confidence intervals for three primary efficacy endpoints. Ipratropium bromide/albuterol Respimat â inhaler group was superior to the ipratropium Respimat â inhaler group with a difference of 0.047 l (P < 0.0001) at 0e4 h. albuterol in the currently marketed product ipratropium bromide/albuterol MDI (Combivent â MDI) as well as the marketed mono-products (34 mcg ipratropium and 180 mcg albuterol base). Ipratropium bromide Respimat â inhaler (20 mcg) has been shown to be clinically comparable to ipratropium bromide MDI (36 mcg Atrovent â CFC Inhalation Aerosol). 13 Our results indicate that after 12 weeks of treatment equivalent bronchodilation was achieved with ipratropium bromide/albuterol via Respimat â inhaler and ipratropium bromide/albuterol via MDI. Additionally, the bronchodilator combination via Respimat â inhaler produced greater bronchodilation than ipratropium alone administered by this inhaler. Albuterol and ipratropium delivered by Respimat â inhaler and MDI also had similar efficacy in peak FEV 1 response, median time to onset of therapeutic response, median duration of therapeutic response, and percentage of patients who achieved a therapeutic response within two hours of administration. The fixed combination treatment via either Respimat â inhaler or MDI reduced the median time to onset of therapeutic response and median time to peak response and prolonged the median duration of therapeutic response compared to ipratropium alone given The overall adverse event frequencies were comparable across treatment groups, with slightly higher frequencies in the ipratropium bromide/albuterol MDI treated patients. Lower respiratory system events were the most frequently reported events and were comprised mainly of COPD exacerbations. These events occurred at comparable rates in the ipratropium bromide/albuterol groups and a slightly lower frequency in the ipratropium Respimat â inhaler treated patients. The most commonly reported SAE was COPD exacerbation (2.2%), which was distributed evenly across treatment groups; this finding is consistent with previous studies of similar patient groups.
14e17 There was also a low rate of discontinuation due to adverse events with no notable differences in discontinuation patterns between treatment groups, and the majority of events causing discontinuation in the trial were lower respiratory system disorders. Adverse events consistent with potential anticholinergic (ipratropium) class events were observed infrequently and occurred similarly across all three treatment groups. Headache, consistent with the possible beta agonist class effect of albuterol, was the most commonly reported adverse event in this trial and occurred with the highest frequency in the ipratropium Respimat â inhaler group (the group with no beta agonist administration). Overall, there were no clinically significant differences in the safety profiles among ipratropium bromide/albuterol Respimat â inhaler, ipratropium bromide/albuterol MDI, and the ipratropium Respimat â inhaler. All three treatments were welltolerated.
A patient assessment questionnaire showed that the majority of patients in the trial preferred the Respimat There were no noticeable differences among the three treatment groups. AE, adverse event. a All primary system organ classes are defined by MedDRA with the exception of 'Respiratory, thoracic and mediastinal disorders' which are divided into separate categories of respiratory system disorders, Lower, Upper and Other.
b Collapsed terms include multiple MedDRA preferred terms.
